Long-Term but Not Short-Term p38 Mitogen-Activated Protein Kinase Inhibition Improves Cardiac Function and Reduces Cardiac Remodeling Post-Myocardial Infarction

No abstract is available for this paper.

• Publication year

  2008

• Venue

  Journal of Pharmacology and Experimental Therapeutics

• Publication date

  2008-06-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1124/jpet.107.133546PMID 18334667
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Role of p38 mitogen‐activated protein kinase in cardiac remodelling

  2007cited by this paper
• FGF1/p38 MAP kinase inhibitor therapy induces cardiomyocyte mitosis, reduces scarring, and rescues function after myocardial infarction

  2006cited by this paper
• Analysis of Properties of Small Heat Shock Protein Hsp25 in MAPK-activated Protein Kinase 2 (MK2)-deficient Cells

  2006cited by this paper
• Heat shock proteins as emerging therapeutic targets

  2005cited by this paper
• p38 MAP Kinase Mediates Inflammatory Cytokine Induction in Cardiomyocytes and Extracellular Matrix Remodeling in Heart

  2005cited by this paper
• Inhibition of p38 mitogen-activated protein kinase protects the heart against cardiac remodeling in mice with heart failure resulting from myocardial infarction.

  2005influential reference
• Effect of rho-kinase inhibition on collagen production in isolated cardiac fibroblasts

  2005cited by this paper
• Focus on small molecule inhibitors for treatment of inflammatory and autoimmune diseases.

  2004cited by this paper
• A novel series of p38 MAP kinase inhibitors for the potential treatment of rheumatoid arthritis.

  2004cited by this paper
• Strong inhibition of TNF-α production and inhibition of IL-8 and COX-2 mRNA expression in monocyte-derived macrophages by RWJ 67657, a p38 mitogen-activated protein kinase (MAPK) inhibitor

  2004cited by this paper
• Targeted Anticytokine Therapy in Patients With Chronic Heart Failure: Results of the Randomized Etanercept Worldwide Evaluation (RENEWAL)

  2004cited by this paper
• p38 mitogen-activated protein kinase inhibition improves cardiac function and attenuates left ventricular remodeling following myocardial infarction in the rat.

  2004cited by this paper
• Myocardial heat shock protein changes in the failing heart following coronary artery ligation.

  2003cited by this paper
• Randomized, Double-Blind, Placebo-Controlled, Pilot Trial of Infliximab, a Chimeric Monoclonal Antibody to Tumor Necrosis Factor-&agr;, in Patients With Moderate-to-Severe Heart Failure: Results of the Anti-TNF Therapy Against Congestive Heart failure (ATTACH) Trial

  2003cited by this paper
• MAP Kinase Kinase 6‐p38 MAP Kinase Signaling Cascade Regulates Cyclooxygenase‐2 Expression in Cardiac Myocytes In Vitro and In Vivo

  2003cited by this paper
• Pharmacological Modulation of Cardiovascular Remodeling: A Guide to Heart Failure Therapy

  2003cited by this paper
• Inositol Polyphosphate 1-Phosphatase Is a Novel Antihypertrophic Factor*

  2002cited by this paper
• Echocardiographic assessment of LV hypertrophy and function in aortic-banded mice: necropsy validation.

  2002cited by this paper
• Adenoviral-Directed Expression of the Type 1A Angiotensin Receptor Promotes Cardiomyocyte Hypertrophy via Transactivation of the Epidermal Growth Factor Receptor

  2002cited by this paper
• p38 MAPK inhibition reduces myocardial reperfusion injury via inhibition of endothelial adhesion molecule expression and blockade of PMN accumulation.

  2002cited by this paper
• Combined angiotensin and endothelin receptor blockade attenuates adverse cardiac remodeling post-myocardial infarction in the rat: possible role of transforming growth factor beta(1).

  2001cited by this paper
• Hypertensive End-Organ Damage and Premature Mortality Are p38 Mitogen-Activated Protein Kinase–Dependent in a Rat Model of Cardiac Hypertrophy and Dysfunction

  2001cited by this paper
• Activation of Cardiac c-Jun NH2-Terminal Kinases and p38-Mitogen-Activated Protein Kinases With Abrupt Changes in Hemodynamic Load

  2001cited by this paper
• The in vivo role of p38 MAP kinases in cardiac remodeling and restrictive cardiomyopathy

  2001cited by this paper
• Suppression of the clinical and cytokine response to endotoxin by RWJ‐67657, a p38 mitogen‐activated protein‐kinase inhibitor, in healthy human volunteers

  2001cited by this paper
• Induction of cardiac fibrosis by transforming growth factor-beta(1).

  2000cited by this paper
• Lidocaine and surgical modification reduces mortality in a rat model of cardiac failure induced by coronary artery ligation.

  2000cited by this paper
• Angiotensin converting enzyme inhibitors block mitogenic signalling pathways in rat cardiac fibroblasts

  1999cited by this paper
• Activation of c-Jun N-terminal kinases and p38-mitogen-activated protein kinases in human heart failure secondary to ischaemic heart disease.

  1999cited by this paper
• An Inhibitor of p38 Mitogen-activated Protein Kinase Protects Neonatal Cardiac Myocytes from Ischemia*

  1999cited by this paper
• Inhibition of p38 mitogen-activated protein kinase decreases cardiomyocyte apoptosis and improves cardiac function after myocardial ischemia and reperfusion.

  1999cited by this paper
• RWJ 67657, a potent, orally active inhibitor of p38 mitogen-activated protein kinase.

  1999cited by this paper
• Dilated cardiomyopathy is associated with significant changes in collagen type I/III ratio.

  1999cited by this paper
• Stimulation of the p38 Mitogen-activated Protein Kinase Pathway in Neonatal Rat Ventricular Myocytes by the G Protein–coupled Receptor Agonists, Endothelin-1 and Phenylephrine: A Role in Cardiac Myocyte Hypertrophy?

  1998cited by this paper
• Activation of mitogen-activated protein kinases and activator protein-1 in myocardial infarction in rats.

  1998cited by this paper
• Cardiac Muscle Cell Hypertrophy and Apoptosis Induced by Distinct Members of the p38 Mitogen-activated Protein Kinase Family*

  1998cited by this paper
• Early versus delayed angiotensin-converting enzyme inhibition in experimental chronic heart failure. Effects on survival, hemodynamics, and cardiovascular remodeling.

  1997cited by this paper
• Dilated cardiomyopathy is associated with an increase in the type I/type III collagen ratio: a quantitative assessment.

  1995cited by this paper
• In vivo co-distribution of fibronectin and actin fibers in granulation tissue: immunofluorescence and electron microscope studies of the fibronexus at the myofibroblast surface

  1984cited by this paper

• Role of Mitogen-Activated Protein (MAP) Kinase Pathways in Metabolic Diseases

  2024cites this paper
• Decorin Induces Cardiac Hypertrophy by Regulating the CaMKII/MEF-2 Signaling Pathway In Vivo

  2021cites this paper
• Prevention of Fibrosis and Pathological Cardiac Remodeling by Salinomycin

  2021cites this paper
• Traditional Chinese medicine as a therapeutic option for cardiac fibrosis: Pharmacology and mechanisms.

  2021cites this paper
• Inhibition of p38 MAP Kinase in Patients with ST-Elevation Myocardial Infarction - Findings from the LATITUDE TIMI 60 Trial.

  2021cites this paper
• Regulators of Cardiac Fibroblast Cell State.

  2020cites this paper
• Myocardial infarction-induced anxiety-like behavior is associated with epigenetic alterations in the hippocampus of rat.

  2020cites this paper
• Zinc homeostasis plays an important role in the prevention of obesity-induced cardiac inflammation, remodeling and dysfunction.

  2020cites this paper
• Study of the mechanism underlying therapeutic effect of Compound Longmaining on myocardial infarction using a network pharmacology-based approach.

  2019cites this paper
• A novel small molecule compound VCP979 improves ventricular remodeling in murine models of myocardial ischemia/reperfusion injury

  2019cites this paper
• Protective transcriptional mechanisms in cardiomyocytes and cardiac fibroblasts.

  2019cites this paper
• Influence of proteasome inhibitor MG-132 on the expression of Hsp 70 and myocardial apoptosis after myocardial infarction

  2018cites this paper
• Angiotensin receptor neprilysin inhibition provides superior cardioprotection compared to angiotensin converting enzyme inhibition after experimental myocardial infarction.

  2018cites this paper
• FPR1 gene silencing suppresses cardiomyocyte apoptosis and ventricular remodeling in rats with ischemia/reperfusion injury through the inhibition of MAPK signaling pathway

  2018cites this paper
• Fibroblast-Specific Genetic Manipulation of p38 Mitogen-Activated Protein Kinase In Vivo Reveals Its Central Regulatory Role in Fibrosis

  2017cites this paper
• A primer on current progress in cardiac fibrosis.

  2017cites this paper
• p38 MAPK Inhibition Improves Heart Function in Pressure‐Loaded Right Ventricular Hypertrophy

  2017cites this paper
• Do p38 mitogen-activated protein kinase inhibitors have a future for the treatment of cardiovascular disease?

  2016cites this paper
• Molecular networks underlying myofibroblast fate and fibrosis.

  2016cites this paper
• Cardiac Fibrosis: The Fibroblast Awakens.

  2016cites this paper
• Transcriptional control of cardiac fibroblast plasticity.

  2016cites this paper
• p38 Mitogen activated protein kinase (MAPK): a new therapeutic target for reducing the risk of adverse pregnancy outcomes

  2016cites this paper
• Attenuation of p38α MAPK stress response signaling delays the in vivo aging of skeletal muscle myofibers and progenitor cells

  2015cites this paper
• Exercise training reduces insulin resistance in postmyocardial infarction rats

  2015cites this paper
• Protein kinases as cardiovascular therapeutic targets.

  2014cites this paper
• p38 mitogen-activated protein kinase and transcription factor GATA-4 in the regulation of cardiomyocyte function

  2014cites this paper
• Myofibroblasts: trust your heart and let fate decide.

  2014cites this paper
• Losmapimod, a novel p38 mitogen-activated protein kinase inhibitor, in non-ST-segment elevation myocardial infarction: a randomised phase 2 trial.

  2014cites this paper
• Attenuation of microglial and neuronal activation in the brain by ICV minocycline following myocardial infarction.

  2014cites this paper
• Design, Synthesis, and Biological Evaluation of Tetra-Substituted Thiophenes as Inhibitors of p38α MAPK

  2014cites this paper
• Amelioration of Cardiac Function and Activation of Anti-Inflammatory Vasoactive Peptides Expression in the Rat Myocardium by Low Level Laser Therapy

  2014cites this paper
• Central nervous system circuits modified in heart failure: pathophysiology and therapeutic implications

  2014cites this paper
• Inflammation in the brain during heart failure

  2013cites this paper
• Caveolin and β1-integrin coordinate angiotensinogen expression in cardiac myocytes.

  2013cites this paper
• Soluble epoxide hydrolase inhibition exerts beneficial anti-remodeling actions post-myocardial infarction.

  2013cites this paper
• Subtotal nephrectomy accelerates pathological cardiac remodeling post-myocardial infarction: implications for cardiorenal syndrome.

  2013cites this paper
• New therapeutic targets in cardiology: p38 alpha mitogen-activated protein kinase for ischemic heart disease.

  2012cites this paper
• Opposing Effects of Age and Calorie Restriction on Molecular Determinants of Myocardial Ischemic Tolerance

  2012cites this paper
• p38 Alpha Mitogen-Activated Protein Kinase for Ischemic Heart Disease

  2012cites this paper
• Role of p38 inhibition in cardiac ischemia/reperfusion injury

  2012cites this paper
• Sustained activation of microglia in the hypothalamic PVN following myocardial infarction.

  2012cites this paper
• Mitogen-activated protein kinase and natural phenolic compounds in cardiovascular remodeling

  2012cites this paper
• Ethylacetate extract of Aquilaria crassna preserve actin cytoskeleton on simulated ischemia induced cardiac cell death

  2012cites this paper
• Peptidomic profiles of post myocardial infarction rats affinity depleted plasma using matrix-assisted laser desorption/ionization time of flight (MALDI-ToF) mass spectrometry

  2012cites this paper
• Basic Science for Clinicians New Therapeutic Targets in Cardiology p38 Alpha Mitogen-Activated Protein Kinase for Ischemic Heart Disease

  2012cites this paper
• Targeting fibrosis for the treatment of heart failure: a role for transforming growth factor-β.

  2012cites this paper
• Diabetic cardiomyopathy and post-infarct ventricular remodelling Effects of levosimendan in a rodent model of type II diabetes

  2011cites this paper
• Le diabète de type 1 diminue la réponse compensatrice après un infarctus du myocarde. Rôle de l'hypothyroïdie tissulaire et effets de l'administration d'hormones thyroïdiennes

  2011cites this paper
• Scutellarin alleviates interstitial fibrosis and cardiac dysfunction of infarct rats by inhibiting TGFβ1 expression and activation of p38‐MAPK and ERK1/2

  2011influential citation
• Therapeutic regulation of cardiac fibroblast function: targeting stress-activated protein kinase pathways.

  2011cites this paper
• [Type 1 diabetes impairs compensatory response after myocardial infarction; role of tissue hypothyroidism and effects of thyroid hormone administration].

  2011cites this paper
• Chronic Kidney Disease-Induced Cardiac Fibrosis Is Ameliorated by Reducing Circulating Levels of a Non-Dialysable Uremic Toxin, Indoxyl Sulfate

  2011cites this paper
• Multifarious molecular signaling cascades of cardiac hypertrophy: can the muddy waters be cleared?

  2010cites this paper
• Mitogen-activated protein kinase signaling in the heart: angels versus demons in a heart-breaking tale.

  2010cites this paper
• Chronic urotensin II receptor antagonist treatment does not alter hypertrophy or fibrosis in a rat model of pressure-overload hypertrophy.

  2010cites this paper
• Microglia activation in the hypothalamic PVN following myocardial infarction.

  2010cites this paper
• Effect of Targeting Mitogen-Activated Protein Kinase on Cardiac Remodeling in Rats

  2009cites this paper